PE20130489A1 - Derivados anticancerosos, su preparacion y su aplicacion terapeutica - Google Patents
Derivados anticancerosos, su preparacion y su aplicacion terapeuticaInfo
- Publication number
- PE20130489A1 PE20130489A1 PE2013000135A PE2013000135A PE20130489A1 PE 20130489 A1 PE20130489 A1 PE 20130489A1 PE 2013000135 A PE2013000135 A PE 2013000135A PE 2013000135 A PE2013000135 A PE 2013000135A PE 20130489 A1 PE20130489 A1 PE 20130489A1
- Authority
- PE
- Peru
- Prior art keywords
- alk
- alkyl
- etoxy
- halogen
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A CONJUGADOS DE DIMEROS DE PIRROLO[1,4]BENZODIAZEPINA DE FORMULA (I) DONDE U Y U' ESTAN AUSENTES O SON CADA UNO H; W Y W' SON CADA UNO H, OH, SH, CN, HALOGENO, ENTRE OTROS; R1 Y R2 O R1' Y R2' FORMAN JUNTOS UN ENLACE DOBLE =CH2 O =CH-CH3 O SON CADA UNO H, HALOGENO O ALQUILO(C1-C6); ALK Y ALK' SON ALQUILENO(C1-C6); Y E Y' SON CADA UNO H U -OR, EN DONDE R Y R' SON CADA UNO H, ALQUILO(C1-C6) O ARILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, CN, CF3, ENTRE OTROS; M ES CH O N; k ES DE 0 A 40; L1 ES UN ENLACE SENCILLO, D-ALK(C1-C6) UNIDO AL CICLO FENILO O PIRIDINILO, ENTRE OTROS, EN DONDE D ES O, NH O N-ALQUILO(C1-C4); L2 ES ALK(C1-C6), ENTRE OTROS; Q ES UN ENLACE SENCILLO O C(=O); G ES -OR O -NRR'; GCR1 ES -C(=O)-ZbRb, ENTRE OTROS, EN DONDE Zb ES UN ENLACE SENCILLO, -O- O -NH-; Rb ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-([2-(2,6-BIS-[(S)-2-ET-(E)-ILIDEN-7-DIMETOXI-1,2,3,11a-TETRAHIDROPIRROLO[2,1c][1,4]BENZODIAZEPIN-5-ONA-8-ILOXIMETIL]-PIRIDIN-4-ILOXI)-ETIL]-(3-{2-[2-(2-MORFOLIN-4-IL-ETOXI)-ETOXI]-ETOXI}-PROPIONIL)-AMINO)-BUTANOATO DE METILO; ACIDO 3-([2-(2,6-BIS-[(S)-2-ET-(E)-ILIDEN-7-DIMETOXI-1,2,3,11a-TETRAHIDRO-PIRROLO[2,1c][1,4]BENZODIAZEPIN-5-ONA-8-ILOXIMETIL]-PIRIDIN-4-ILOXI)-ETIL]-{2-[2-(2-METOXI-ETOXI)-ETOXI]-ETIL}-AMINO)-PROPANOICO; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1056103A FR2963007B1 (fr) | 2010-07-26 | 2010-07-26 | Derives anticancereux, leur preparation et leur application therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130489A1 true PE20130489A1 (es) | 2013-05-08 |
Family
ID=43027561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000135A PE20130489A1 (es) | 2010-07-26 | 2011-07-25 | Derivados anticancerosos, su preparacion y su aplicacion terapeutica |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9056914B2 (es) |
| EP (1) | EP2598507B1 (es) |
| JP (1) | JP5814366B2 (es) |
| KR (1) | KR20130094806A (es) |
| CN (1) | CN103140491B (es) |
| AR (1) | AR082341A1 (es) |
| AU (1) | AU2011284339B2 (es) |
| BR (1) | BR112013001978B1 (es) |
| CA (1) | CA2806665A1 (es) |
| CL (1) | CL2013000250A1 (es) |
| CO (1) | CO6650375A2 (es) |
| CR (1) | CR20130035A (es) |
| DO (1) | DOP2013000021A (es) |
| EA (1) | EA201390162A1 (es) |
| EC (1) | ECSP13012404A (es) |
| ES (1) | ES2638520T3 (es) |
| FR (1) | FR2963007B1 (es) |
| GT (1) | GT201300025A (es) |
| MA (1) | MA34469B1 (es) |
| MX (1) | MX2013001069A (es) |
| MY (1) | MY159197A (es) |
| NI (1) | NI201300010A (es) |
| NZ (1) | NZ606246A (es) |
| PE (1) | PE20130489A1 (es) |
| SG (1) | SG187191A1 (es) |
| TW (1) | TW201208689A (es) |
| UA (1) | UA111164C2 (es) |
| UY (1) | UY33531A (es) |
| WO (1) | WO2012014147A1 (es) |
| ZA (1) | ZA201300685B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2949469A1 (fr) * | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| CA2885340C (en) | 2012-10-12 | 2016-11-08 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| CN105307685B (zh) * | 2013-03-13 | 2019-03-08 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓和其结合物 |
| CN105142674B (zh) * | 2013-03-13 | 2018-11-13 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓和其结合物 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| ES2830385T3 (es) | 2014-09-12 | 2021-06-03 | Genentech Inc | Anticuerpos e inmunoconjugados anti-HER2 |
| CA2957148A1 (en) * | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
| TW201632531A (zh) | 2015-01-14 | 2016-09-16 | 必治妥美雅史谷比公司 | 苯二氮呯二聚物，其結合物及製造與使用方法 |
| BR112017014937A2 (pt) | 2015-01-14 | 2018-03-13 | Bristol-Myers Squibb Company | dímeros de benzodiazepina ligados em ponte a heteroarileno, conjugados dos mesmos, e métodos de preparação e uso |
| EP3313854A1 (en) | 2015-06-23 | 2018-05-02 | Bristol-Myers Squibb Company | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| DK3612537T3 (da) | 2017-04-18 | 2022-08-08 | Medimmune Ltd | Pyrrolobenzodiazepinkonjugater |
| SG11202000358YA (en) | 2017-08-18 | 2020-02-27 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| EP3690038A4 (en) | 2017-09-29 | 2021-05-19 | Daiichi Sankyo Company, Limited | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CN115466231B (zh) * | 2022-10-23 | 2024-03-08 | 浙江大学 | 管道化制备3-[2-(4-吗啉基)乙氧基]丙腈的方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1516743A (fr) | 1966-04-01 | 1968-02-05 | Rhone Poulenc Sa | Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus |
| US4981979A (en) | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
| JPH04502469A (ja) | 1988-12-22 | 1992-05-07 | ゾマ コーポレイション | ヒンダードカップリング剤および方法 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| US7049311B1 (en) | 1998-08-27 | 2006-05-23 | Spirogen Limited | Pyrrolbenzodiazepines |
| DE60336149D1 (de) | 2002-08-16 | 2011-04-07 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
| NZ539395A (en) | 2002-11-07 | 2009-01-31 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| EP3524611B1 (en) | 2003-05-20 | 2020-12-30 | ImmunoGen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
| DK1660513T5 (da) | 2003-07-21 | 2011-07-18 | Immunogen Inc | CA6 antigen-specifikt, cytotoksisk konjugat og fremgangsmåder til anvendelse heraf |
| WO2005040170A2 (en) | 2003-10-22 | 2005-05-06 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| GB0404577D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2005085260A1 (en) | 2004-03-09 | 2005-09-15 | Spirogen Limited | Pyrrolobenzodiazepines |
| EP1669358A1 (en) | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
| CA2927595C (en) | 2004-12-22 | 2023-01-31 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| EP1813614B1 (en) * | 2006-01-25 | 2011-10-05 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives |
| WO2007093873A1 (en) * | 2006-02-13 | 2007-08-23 | Council Of Scientific And Industrial Research | Bis-pyrr0l0[2,l-c] [1, 4] benzodiazepine- anthraquinone conjugates as antitumour agents and a process for the preparation thereof |
| EP1832577A1 (en) | 2006-03-07 | 2007-09-12 | Sanofi-Aventis | Improved prodrugs of CC-1065 analogs |
| EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| ES2435779T3 (es) * | 2007-07-19 | 2013-12-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| BRPI0910746B8 (pt) | 2008-04-30 | 2021-05-25 | Immunogen Inc | agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica |
| CN104258413A (zh) | 2008-04-30 | 2015-01-07 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
| FR2939795B1 (fr) | 2008-12-17 | 2010-12-17 | Sanofi Aventis | Procede de preparation d'esters actives |
| ES2604668T3 (es) * | 2009-02-05 | 2017-03-08 | Immunogen, Inc. | Nuevos derivados de benzodiacepina |
| AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
-
2010
- 2010-07-26 FR FR1056103A patent/FR2963007B1/fr not_active Expired - Fee Related
-
2011
- 2011-07-25 SG SG2013005855A patent/SG187191A1/en unknown
- 2011-07-25 EA EA201390162A patent/EA201390162A1/ru unknown
- 2011-07-25 MX MX2013001069A patent/MX2013001069A/es not_active Application Discontinuation
- 2011-07-25 PE PE2013000135A patent/PE20130489A1/es not_active Application Discontinuation
- 2011-07-25 AR ARP110102680A patent/AR082341A1/es unknown
- 2011-07-25 JP JP2013521272A patent/JP5814366B2/ja active Active
- 2011-07-25 NZ NZ60624611A patent/NZ606246A/en not_active IP Right Cessation
- 2011-07-25 ES ES11749535.8T patent/ES2638520T3/es active Active
- 2011-07-25 CA CA2806665A patent/CA2806665A1/en not_active Abandoned
- 2011-07-25 UA UAA201302391A patent/UA111164C2/uk unknown
- 2011-07-25 MA MA35664A patent/MA34469B1/fr unknown
- 2011-07-25 KR KR1020137004626A patent/KR20130094806A/ko not_active Application Discontinuation
- 2011-07-25 WO PCT/IB2011/053310 patent/WO2012014147A1/en active Application Filing
- 2011-07-25 CN CN201180046298.4A patent/CN103140491B/zh active Active
- 2011-07-25 EP EP11749535.8A patent/EP2598507B1/en active Active
- 2011-07-25 MY MYPI2013000240A patent/MY159197A/en unknown
- 2011-07-25 AU AU2011284339A patent/AU2011284339B2/en not_active Ceased
- 2011-07-25 BR BR112013001978-6A patent/BR112013001978B1/pt not_active IP Right Cessation
- 2011-07-26 TW TW100126452A patent/TW201208689A/zh unknown
- 2011-07-26 UY UY0001033531A patent/UY33531A/es not_active Application Discontinuation
-
2013
- 2013-01-22 NI NI201300010A patent/NI201300010A/es unknown
- 2013-01-23 GT GT201300025A patent/GT201300025A/es unknown
- 2013-01-24 CO CO13013434A patent/CO6650375A2/es not_active Application Discontinuation
- 2013-01-24 DO DO2013000021A patent/DOP2013000021A/es unknown
- 2013-01-24 EC ECSP13012404 patent/ECSP13012404A/es unknown
- 2013-01-25 ZA ZA2013/00685A patent/ZA201300685B/en unknown
- 2013-01-25 US US13/750,691 patent/US9056914B2/en active Active
- 2013-01-25 CL CL2013000250A patent/CL2013000250A1/es unknown
- 2013-01-29 CR CR20130035A patent/CR20130035A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130489A1 (es) | Derivados anticancerosos, su preparacion y su aplicacion terapeutica | |
| PE20130590A1 (es) | Derivados de tomaimicina como agentes citotoxicos | |
| MX2011011875A (es) | Compuesto de carboxamida heterociclica diamino. | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| PE20080130A1 (es) | Benzoimidazol-2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina | |
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| PE20140630A1 (es) | Derivados de acido 3-fenilpropionico ramificados y su uso | |
| PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
| BRPI0518159A (pt) | antagonistas de receptor de trombina | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| PE20091408A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20081164A1 (es) | Nuevos compuestos 521 | |
| EA200602058A1 (ru) | Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
| PE20140913A1 (es) | Inhibidores de nampt y rock | |
| PE20120992A1 (es) | Conjugados de dimeros de pirrolo[1,4] benzodiazepina como agentes anticancerosos | |
| PE20091175A1 (es) | Derivados bis-(sulfonilamino) en terapia 205 | |
| PE20051046A1 (es) | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| PE20070115A1 (es) | Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas | |
| PE20120110A1 (es) | [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa | |
| PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
| ATE464309T1 (de) | Indolizinderivate und deren verwendung als crth2- antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |